guidance

Hikma has strong start to 2024, with continued momentum across all businesses. Full year guidance reiterated

Hikma has strong start to 2024, with continued momentum across all businesses. Full year guidance reiterated

Hikma has strong start to 2024, with continued momentum across all businesses. Full year guidance reiterated

AETOSWire April 25, 2024

Amman, Jordan Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current...

Hikma continues strong momentum across the Group and upgrades guidance for 2023

Hikma continues strong momentum across the Group and upgrades guidance for 2023

AETOSWire November 2, 2023

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update...

Hikma delivers strong H1 performance and raises Generics guidance Growth in all three businesses and across all geographies

Hikma delivers strong H1 performance and raises Generics guidance Growth in all three businesses and across all geographies

Hikma delivers strong H1 performance and raises Generics guidance Growth in all three businesses and across all geographies

AETOSWire August 3, 2023

Hikma Pharmaceuticals PLC and its subsidiaries (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, report its interim results...

Good momentum across all businesses and updated Generics guidance

Good momentum across all businesses and updated Generics guidance

AETOSWire April 29, 2023

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update...

Hikma reiterates full year segmental guidance, with strong momentum in Injectables and Branded

Hikma reiterates full year segmental guidance, with strong momentum in Injectables and Branded

AETOSWire November 3, 2022

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update...

Hikma continued strategic progress and updated full-year guidance following Custopharm acquisition

Hikma continued strategic progress and updated full-year guidance following Custopharm acquisition

Hikma continued strategic progress and updated full-year guidance following Custopharm acquisition

AETOSWire April 29, 2022

London, England – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on...